体内
PARP抑制剂
癌症研究
聚ADP核糖聚合酶
癌症
生物
化学
病毒学
细胞生物学
医学
DNA
生物化学
内科学
聚合酶
生物技术
作者
Joan Kyula,Victoria Roulstone,James C. Wright,Francesca Butera,Arnaud J. Legrand,Richard Elliott,Martin McLaughlin,Galabina Bozhanova,Dragomir B. Krastev,Stephen J. Pettitt,Tencho Tenev,Magnus T. Dillon,Shane Foo,Emmanuel C. Patin,Victoria A. Jennings,Charleen Chan Wah Hak,Elizabeth Appleton,Amarin Wongariyapak,Malin Pedersen,Antonio Rullan
标识
DOI:10.1038/s41467-025-61297-w
摘要
Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit. RT3D interacts with retinoic acid-induced gene-1 (RIG-I) and activates PARP-1, with consequent PARylation of components of the extrinsic apoptosis pathway. Pharmacological or genetic inhibition of PARP-1 abrogates this PARylation and enhances extrinsic apoptosis, NF-kB signalling and pro-inflammatory cell death. Interaction between PARP-1 and RIG-I induced by treating RT3D-infected cells with talazoparib activates downstream IFN-β and TNF/TRAIL production to amplify the therapeutic effect through positive feedback. Furthermore, the effect of RT3D-talazoparib combination is phenocopied by non-viral ds-RNA therapy and RIG-I agonism. In vivo, mouse tumour model results show that RT3D/talazoparib combination regimen induces complete control of inoculated tumour as well as protection from subsequent tumour rechallenge with the, with accompanied innate and adaptive immune activation.
科研通智能强力驱动
Strongly Powered by AbleSci AI